On March 12th, Genetic Analysis AS (”Genetic Analysis” or the ”Company”) announced the launch of GA-map® Dysbiosis Test AInsight (”AInsight”), an AI-assisted interpretation platform designed to translate microbiome analysis results into structured and clinically relevant insights. The platform utilizes an AI language model restricted exclusively to Genetic Analysis curated Bacteria Compendium, supporting automated generation of structured interpretation reports for individual microbiome profiles and enabling scalable report generation for laboratory workflows.
Analyst Group’s View on the Launch of GA-map® Dysbiosis Test AInsight
Analyst Group views the launch of AInsight positively, as the platform is expected to address one of the key practical barriers to broader clinical adoption of the GA-map® Dysbiosis Test, namely the complexity of interpreting microbiome results in routine healthcare settings. The GA-map® Dysbiosis Test is Genetic Analysis’ flagship product and the primary revenue driver for the Company. The test is a CE-IVD approved molecular diagnostic assay that profiles a patient’s gut microbiome and evaluates intestinal dysbiosis by comparing the microbiome profile to a healthy reference population, generating results through a Dysbiosis Index score. As the only CE-IVD marked and patented routine diagnostic test for microbiome analysis, the GA-map® Dysbiosis Test has been the foundation of Genetic Analysis’ commercial strategy for more than a decade and is supported by more than 50 peer-reviewed publications and over 70 clinical studies. Recurring reagent kit sales derived from the test have grown from NOK 2.9m in 2020 to NOK 14.1m in 2025, corresponding to a CAGR of 37%, and constitute the single most important revenue stream for the Company.
Analyst Group has previously emphasized that a market shift toward routine diagnostic use of microbiome testing is expected to be gradual, as adoption requires time and the interpretation of complex microbial profiles has presented a practical challenge for healthcare professionals unfamiliar with microbiome data, where AInsight directly addresses this barrier. By contextualizing deviations in bacterial abundance using curated scientific evidence and automating the generation of structured interpretation reports, the platform is expected to lower the threshold for clinical implementation of the GA-map® Dysbiosis Test. This is strategically significant, as the more accessible the test becomes to interpret, the more compelling the case for new laboratories to adopt the GA-map® platform, which in turn is expected to drive recurring demand for high-margin reagent kits. A key aspect of the design is that the AI model operates within a closed and controlled framework, restricted to Genetic Analysis Bacteria Compendium, which ensures clinical reliability and alignment with the validated science underpinning the test, an important distinction in a field where reliability concerns have been raised around less standardized solutions.
From a scalability perspective, AInsight is also expected to benefit existing customers. Laboratories already running the GA-map® Dysbiosis Test are expected to handle increasing testing volumes more efficiently, as the platform supports automated and scalable report generation. This is expected to reduce the operational friction associated with interpreting results at scale, which Analyst Group assesses could support both deeper utilization among current laboratory customers and a stronger sales argument when targeting new ones. Given that Genetic Analysis’ business model is built on installing the GA-map® platform at laboratories and generating recurring revenue from reagent kits, any initiative that enhances the usability and scalability of the platform is expected to have positive implications for long-term revenue growth.
Analyst Group does not anticipate that AInsight alone will have a direct material impact on the Company’s near-term financials or prompt a revision of current estimates, which project revenue growing from NOK 16.7m in 2025 to NOK 43.2m in 2028. Rather, the launch is assessed as a strategic enabler that is expected to strengthen the commercial proposition of the GA-map® Dysbiosis Test over the medium to long term. In the context of the broader GA-map® platform strategy, AInsight complements a series of recent milestones, including the launch of GA-map® MHI GutHealth in H2-25 and the anticipated launch of GA-map® IBD Precision Dx in H1-26, that collectively reinforce the Company’s ambition to expand clinical adoption and grow its installed laboratory base.
In summary, Analyst Group views the launch of GA-map® Dysbiosis Test AInsight as a strategically important step that is expected to strengthen the commercial appeal of the GA-map® platform among both existing and prospective laboratory customers, supporting continued growth in high-margin, recurring reagent kit revenues over the medium to long term. While no immediate revision to financial estimates is warranted, Analyst Group assesses the launch as a meaningful initiative that reinforces the Company’s strategy and long-term growth outlook.
